{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:49:11Z","timestamp":1793998151465,"version":"4.8.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["17\/67\/01"],"award-info":[{"award-number":["17\/67\/01"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Bacterial infection is a major cause of mortality in patients with cirrhosis. Spontaneous bacterial peritonitis (SBP) is a serious and common infection in patients with cirrhosis and ascites. Secondary prophylactic antibiotic therapy has been shown to improve outcomes after an episode of SBP but primary prophylaxis to prevent the first episode of SBP remains contentious. The aim of this trial is to assess whether primary antibiotic prophylaxis with co-trimoxazole improves overall survival compared to placebo in adults with cirrhosis and ascites.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The ASEPTIC trial is a multicentre, placebo-controlled, double-blinded, randomised controlled trial (RCT) in England, Scotland, and Wales. Patients aged 18\u00a0years and older with cirrhosis and ascites requiring diuretic treatment or paracentesis, and no current or previous episodes of SBP, are eligible, subject to exclusion criteria. The trial aims to recruit 432 patients from at least 30 sites. Patients will be randomised in a 1:1 ratio to receive either oral co-trimoxazole 960\u00a0mg or an identical placebo once daily for 18\u00a0months, with 6 monthly follow-up visits thereafter (with a maximum possible follow-up period of 48\u00a0months, and a minimum of 18\u00a0months). The primary outcome is overall survival. Secondary outcomes include the time to the first incidence of SBP, hospital admission rates, incidence of other infections (including <jats:italic>Clostridium difficile<\/jats:italic>) and antimicrobial resistance, patients\u2019 health-related quality of life, health and social care resource use, incidence of cirrhosis-related decompensation events, liver transplantation, and treatment-related serious adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This trial will investigate the efficacy, safety, and cost-effectiveness of co-trimoxazole for patients with liver cirrhosis and ascites to determine whether this strategy improves clinical outcomes. Given there are no treatments that improve survival in decompensated cirrhosis outside of liver transplant, if the trial has a positive outcome, we anticipate widespread adoption of primary antibiotic prophylaxis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/show\/NCT04395365\">NCT043955365<\/jats:ext-link>. Registered on 18 April 2020. Research ethical approval was granted by the Research Ethics Committee (South Central \u2013 Oxford B; REC 19\/SC\/0311) and the Medicines and Healthcare products Regulatory Agency (MHRA).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06727-6","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T07:05:14Z","timestamp":1664262314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["ASEPTIC: primary antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis\u2014study protocol for an interventional randomised controlled trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Dominic","family":"Crocombe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norin","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indran","family":"Balakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Bordea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"China","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynsey","family":"Corless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Danquah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim-Moulay","family":"Dehbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewan H.","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Freemantle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Peter","family":"Gear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coral","family":"Hollywood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasheeka","family":"Jeyapalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiannis","family":"Kallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"McPherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Portal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Ryder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Virk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"issue":"3","key":"6727_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137.","journal-title":"Ann Intern Med"},{"issue":"2","key":"6727_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/gutjnl-2011-300779","volume":"61","author":"R Wiest","year":"2012","unstructured":"Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut. 2012;61(2):297\u2013310.","journal-title":"Gut"},{"issue":"6","key":"6727_CR3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s00134-012-2523-2","volume":"38","author":"AJ O\u2019Brien","year":"2012","unstructured":"O\u2019Brien AJ, Welch CA, Singer M, Harrison DA. Prevalence and outcome of cirrhosis patients admitted to UK intensive care: a comparison against dialysis-dependent chronic renal failure patients. Intensive Care Med. 2012;38(6):991\u20131000.","journal-title":"Intensive Care Med"},{"issue":"5","key":"6727_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1365-2036.2011.04746.x","volume":"34","author":"NC Chavez-Tapia","year":"2011","unstructured":"Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, Soares-Weiser K, Mendez-Sanchez N, Gluud C, et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review. Aliment Pharmacol Ther. 2011;34(5):509\u201318.","journal-title":"Aliment Pharmacol Ther"},{"key":"6727_CR5","doi-asserted-by":"publisher","unstructured":"Cohen MJ, Sahar T, Benenson S, Elinav E, Brezis M, Soares-Weiser K. Antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhotic patients with ascites, without gastro-intestinal bleeding. Cochrane Database Syst Rev. 2009;(2):CD004791. https:\/\/doi.org\/10.1002\/14651858.CD004791.pub2.","DOI":"10.1002\/14651858.CD004791.pub2"},{"key":"6727_CR6","unstructured":"NICE. NICE guideline NG50 | Cirrhosis in over 16s: assessment and management | Guidance | NICE. NICE. Available from: https:\/\/www.nice.org.uk\/guidance\/ng50\/resources\/endorsed-resource-practical-implications-for-primary-care-nice-guideline-ng50-4540284541. Cited 2022 Jan 29."},{"issue":"3","key":"6727_CR7","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/hep.1840210312","volume":"21","author":"A Rimola","year":"1995","unstructured":"Rimola A, Salmer\u00f3n JM, Clemente G, Rodrigo L, Obrador A, Miranda ML, et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology. 1995;21(3):674\u20139.","journal-title":"Hepatology"},{"issue":"3","key":"6727_CR8","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/hep.1840160318","volume":"16","author":"J Llach","year":"1992","unstructured":"Llach J, Rimola A, Navasa M, Gin\u00e8s P, Salmer\u00f3n JM, Gin\u00e8s A, et al. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology. 1992;16(3):724\u20137.","journal-title":"Hepatology"},{"issue":"4","key":"6727_CR9","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/0016-5085(93)90284-J","volume":"104","author":"M Andreu","year":"1993","unstructured":"Andreu M, Sola R, Sitges-Serra A, Alia C, Gallen M, Vila MC, et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology. 1993;104(4):1133\u20138.","journal-title":"Gastroenterology"},{"issue":"2","key":"6727_CR10","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1053\/gast.1999.0029900414","volume":"117","author":"C Guarner","year":"1999","unstructured":"Guarner C, Sol\u00e0 R, Soriano G, Andreu M, Novella MT, Vila MC, et al. Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels. Gastroenterology. 1999;117(2):414\u20139.","journal-title":"Gastroenterology"},{"issue":"3","key":"6727_CR11","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/hep.1840080332","volume":"8","author":"BA Runyon","year":"1988","unstructured":"Runyon BA. Patients with deficient ascitic fluid opsonic activity are predisposed to spontaneous bacterial peritonitis. Hepatology. 1988;8(3):632\u20135.","journal-title":"Hepatology"},{"issue":"4","key":"6727_CR12","first-page":"311","volume":"3","author":"C Guarner","year":"1995","unstructured":"Guarner C, Runyon BA. Spontaneous bacterial peritonitis: pathogenesis, diagnosis, and management. Gastroenterologist. 1995;3(4):311\u201328.","journal-title":"Gastroenterologist"},{"issue":"5","key":"6727_CR13","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.jhep.2014.11.036","volume":"62","author":"R Terg","year":"2015","unstructured":"Terg R, Casciato P, Garbe C, Cartier M, Stieben T, Mendizabal M, et al. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study. J Hepatol. 2015;62(5):1056\u201360.","journal-title":"J Hepatol"},{"issue":"2","key":"6727_CR14","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jhep.2015.03.040","volume":"63","author":"T Bruns","year":"2015","unstructured":"Bruns T, Lutz P, Stallmach A, Nischalke HD. Low ascitic fluid protein does not indicate an increased risk for spontaneous bacterial peritonitis in current cohorts. J Hepatol. 2015;63(2):527\u20138.","journal-title":"J Hepatol"},{"issue":"2","key":"6727_CR15","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","volume":"69","author":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu","year":"2018","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406\u201360.","journal-title":"J Hepatol"},{"issue":"11","key":"6727_CR16","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/apt.13172","volume":"41","author":"JB Dever","year":"2015","unstructured":"Dever JB, Sheikh MY. Review article: spontaneous bacterial peritonitis\u2013bacteriology, diagnosis, treatment, risk factors and prevention. Aliment Pharmacol Ther. 2015;41(11):1116\u201331.","journal-title":"Aliment Pharmacol Ther"},{"key":"6727_CR17","doi-asserted-by":"publisher","unstructured":"Runyon BA,\u00a0AASLD.\u00a0Introduction to the revised American Association for the Study of Liver Diseases Practice\u00a0Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57(4):1651\u20133. https:\/\/doi.org\/10.1002\/hep.26359.","DOI":"10.1002\/hep.26359"},{"issue":"1","key":"6727_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/gutjnl-2020-321790","volume":"70","author":"GP Aithal","year":"2021","unstructured":"Aithal GP, Palaniyappan N, China L, H\u00e4rm\u00e4l\u00e4 S, Macken L, Ryan JM, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021;70(1):9\u201329.","journal-title":"Gut"},{"issue":"17","key":"6727_CR19","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","volume":"372","author":"MR Thursz","year":"2015","unstructured":"Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;372(17):1619\u201328.","journal-title":"N Engl J Med"},{"issue":"9","key":"6727_CR20","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa2022166","volume":"384","author":"L China","year":"2021","unstructured":"China L, Freemantle N, Forrest E, Kallis Y, Ryder SD, Wright G, et al. A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med. 2021;384(9):808\u201317.","journal-title":"N Engl J Med"},{"issue":"4","key":"6727_CR21","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1590\/S0004-28032005000400012","volume":"42","author":"RF Alvarez","year":"2005","unstructured":"Alvarez RF, de Mattos AA, Corr\u00eaa EBD, Cotrim HP, Nascimento TVSB. Trimethoprim-sulfamethoxazole versus norfloxacin in the prophylaxis of spontaneous bacterial peritonitis in cirrhosis. Arq Gastroenterol. 2005;42(4):256\u201362.","journal-title":"Arq Gastroenterol"},{"issue":"8","key":"6727_CR22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.7326\/0003-4819-122-8-199504150-00007","volume":"122","author":"N Singh","year":"1995","unstructured":"Singh N, Gayowski T, Yu VL, Wagener MM. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med. 1995;122(8):595\u20138.","journal-title":"Ann Intern Med"},{"issue":"2","key":"6727_CR23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1440-1746.2007.04926.x","volume":"23","author":"S Lontos","year":"2008","unstructured":"Lontos S, Gow PJ, Vaughan RB, Angus PW. Norfloxacin and trimethoprim-sulfamethoxazole therapy have similar efficacy in prevention of spontaneous bacterial peritonitis. J Gastroenterol Hepatol. 2008;23(2):252\u20135.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"6727_CR24","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1053\/gast.1997.v113.pm9322524","volume":"113","author":"J Inadomi","year":"1997","unstructured":"Inadomi J, Sonnenberg A. Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis. Gastroenterology. 1997;113(4):1289\u201394.","journal-title":"Gastroenterology"},{"issue":"4","key":"6727_CR25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1089\/mdr.2016.0318","volume":"24","author":"T Costa","year":"2018","unstructured":"Costa T, Linhares I, Ferreira R, Neves J, Almeida A. Frequency and antibiotic resistance of bacteria implicated in community urinary tract infections in North Aveiro between 2011 and 2014. Microb Drug Resist. 2018;24(4):493\u2013504.","journal-title":"Microb Drug Resist"},{"issue":"11","key":"6727_CR26","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1136\/gutjnl-2011-301835","volume":"61","author":"HM Jafferbhoy","year":"2012","unstructured":"Jafferbhoy HM, Miller MH, Gashau W, Chandrashekar C, Henry EB, Lockhart M, et al. Spontaneous bacterial peritonitis prophylaxis in the era of healthcare associated infection. Gut. 2012;61(11):1644\u20135.","journal-title":"Gut"},{"issue":"9","key":"6727_CR27","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1093\/cid\/cir067","volume":"52","author":"EL Sibanda","year":"2011","unstructured":"Sibanda EL, Weller IVD, Hakim JG, Cowan FM. Does trimethoprim-sulfamethoxazole prophylaxis for HIV induce bacterial resistance to other antibiotic classes? Results of a systematic review. Clin Infect Dis. 2011;52(9):1184\u201394.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"6727_CR28","doi-asserted-by":"publisher","first-page":"e17765","DOI":"10.1371\/journal.pone.0017765","volume":"6","author":"DB Everett","year":"2011","unstructured":"Everett DB, Mukaka M, Denis B, Gordon SB, Carrol ED, van Oosterhout JJ, et al. Ten years of surveillance for invasive Streptococcus pneumoniae during the era of antiretroviral scale-up and cotrimoxazole prophylaxis in Malawi. PLoS ONE. 2011;6(3):e17765.","journal-title":"PLoS ONE"},{"issue":"4","key":"6727_CR29","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s12325-017-0514-y","volume":"34","author":"V Pitiriga","year":"2017","unstructured":"Pitiriga V, Vrioni G, Saroglou G, Tsakris A. The impact of antibiotic stewardship programs in combating quinolone resistance: a systematic review and recommendations for more efficient interventions. Adv Ther. 2017;34(4):854\u201365.","journal-title":"Adv Ther"},{"issue":"10138","key":"6727_CR30","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1016\/S0140-6736(18)30840-7","volume":"391","author":"P Caraceni","year":"2018","unstructured":"Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet. 2018;391(10138):2417\u201329.","journal-title":"Lancet"},{"issue":"46 Suppl 1","key":"6727_CR31","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1086\/521859","volume":"15","author":"RC Owens","year":"2008","unstructured":"Owens RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;15(46 Suppl 1):S19-31.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"6727_CR32","doi-asserted-by":"publisher","first-page":"e0127448","DOI":"10.1371\/journal.pone.0127448","volume":"10","author":"M Merli","year":"2015","unstructured":"Merli M, Lucidi C, Di Gregorio V, Falcone M, Giannelli V, Lattanzi B, et al. The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey. PLoS ONE. 2015;10(5):e0127448.","journal-title":"PLoS ONE"},{"issue":"4","key":"6727_CR33","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/hep.27941","volume":"63","author":"S Piano","year":"2016","unstructured":"Piano S, Fasolato S, Salinas F, Romano A, Tonon M, Morando F, et al. The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: results of a randomized, controlled clinical trial. Hepatology. 2016;63(4):1299\u2013309.","journal-title":"Hepatology"},{"issue":"6","key":"6727_CR34","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1002\/hep.28733","volume":"64","author":"A O\u2019Brien","year":"2016","unstructured":"O\u2019Brien A, China L, Gant V. The potential danger of empiric antimicrobial therapy for nosocomial SBP. Hepatology. 2016;64(6):2267\u20138.","journal-title":"Hepatology"},{"issue":"7","key":"6727_CR35","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/bcp.14193","volume":"86","author":"AHY Chan","year":"2020","unstructured":"Chan AHY, Horne R, Hankins M, Chisari C. The Medication Adherence Report Scale: a measurement tool for eliciting patients\u2019 reports of nonadherence. Br J Clin Pharmacol. 2020;86(7):1281\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"357","key":"6727_CR36","doi-asserted-by":"publisher","first-page":"j2250","DOI":"10.1136\/bmj.j2250","volume":"25","author":"HM Dehbi","year":"2017","unstructured":"Dehbi HM, Royston P, Hackshaw A. Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards. BMJ. 2017;25(357):j2250.","journal-title":"BMJ"},{"issue":"11","key":"6727_CR37","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095\u2013108.","journal-title":"Med Care"},{"key":"6727_CR38","unstructured":"Joint Formulary Committee | About | BNF content published by NICE. Available from: https:\/\/bnf.nice.org.uk\/about\/joint-formulary-committee\/. Cited 2022 Jun 16."},{"key":"6727_CR39","first-page":"185","volume-title":"Unit costs of health and social care 2021","author":"KC Jones","year":"2021","unstructured":"Jones KC, Burns A. Unit costs of health and social care 2021. Kent, UK: Personal Social Services Research Unit; 2021. p. 185.\u00a0Available from:\u00a0https:\/\/www.pssru.ac.uk\/research\/354\/."},{"key":"6727_CR40","unstructured":"National Institute for Health and Care Excellence. Introduction to health technology evaluation | NICE health technology evaluations: the manual | Guidance | NICE. NICE Technology evaluations: the manual (PMG36). NICE; 2022. Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/introduction-to-health-technology-evaluation. Cited 2022 Jun 16."},{"issue":"4","key":"6727_CR41","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1002\/hep.26359","volume":"57","author":"BA Runyon","year":"2013","unstructured":"Runyon BA, AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57(4):1651\u20133.","journal-title":"Hepatology"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06727-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06727-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06727-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T07:06:42Z","timestamp":1664262402000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06727-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6727"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06727-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"assertion":[{"value":"18 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Research ethical approval was granted by Research Ethics Committee (South Central \u2013 Oxford B; REC 19\/SC\/0311) and MHRA. Written, informed consent to participate will be obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable\u2014no identifying images or personal or clinical details of participants are presented here or will be presented in reports of the trial results. Informed consent materials can be made by email to .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"NF has acted as a consultant for Gedeon Richter, Abbott Singapore, Galderma, ALK, AstraZeneca, Ipsen, Vertex, Sanofi, Thea, Aimmune, Novatis, Novo Nordisk, Allergan, Alliance, and MSD. No non-financial conflicts. SM has received consultancy\/speakers fees from Abbvie, Allergan, BMS, Gilead, Intercept, MSD, Novo Nordisk, Norgine, Novartis, and Sequana outside the submitted work. The other authors declared that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"812"}}